BioPharmSignal logoBioPharmSignal

Biotech News

New Two-Year Data from Pivotal ApproaCH Trial Showing Durable Benefits of TransCon® CNP (Navepegritide) in Children with Achondroplasia Shared at ACMG 2026

Ascendis Pharma (ASND)Ascendis PharmaClinical readout

COPENHAGEN, Denmark, March 16, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data from its pivotal ApproaCH Trial showing that children with achondroplasia treated with once-weekly TransCon CNP (navepegritide) maintained consistent improvements in growth through

Related news

ASNDAscendis Pharma2026-05-06 20:01 EST

New 2-Year Data from Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) Show Pronounced Gains in Growth Outcomes in Children with Achondroplasia Aged ≥5 Years

ASNDAscendis Pharma2026-06-30 12:30 EST

Children with Achondroplasia Treated with TransCon CNP Showed Continued Improvements in Lower Extremity Alignment at Week 104 of the Pivotal ApproaCH Trial

View all latest news

Ascendis Pharma

TransCon Technology Ascendis Pharma applies its TransCon prodrug platform to create long-acting therapies that release an unmodified parent drug over time. Its portfolio spans endocrinology, rare growth disorders and oncology. Commercial Endocrinology Portfolio YORVIPATH is a parathyroid-hormone replacement therapy for chronic...

Recent company news

ASNDAscendis Pharma2026-08-13 11:30 EST

Ascendis Pharma Reports Second Quarter 2026 Financial Results

ASNDAscendis Pharma2026-08-06 20:01 EST

Ascendis to Report Second Quarter 2026 Financial Results and Provide Business Update on August 13, 2026

ASNDAscendis Pharma2026-08-06 12:00 EST

Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S.

ASNDAscendis Pharma2026-06-30 12:30 EST

Children with Achondroplasia Treated with TransCon CNP Showed Continued Improvements in Lower Extremity Alignment at Week 104 of the Pivotal ApproaCH Trial

ASNDAscendis Pharma2026-06-26 20:01 EST

Ascendis Joins Multiple Russell U.S. Indexes, Including the Russell 3000®, Russell 1000®, Russell 2500® and Russell Midcap®

Stock data

Close
253.29 USD
Market cap
13.38B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States